semaglutide approved for cardiovascular helps reduce risk of heart attack, stroke in people without diabetes, study finds 🚨 Big news from the

Additional experimental and clinical research in humans is needed in order to elucidate the mechanisms of carnosine application in these diseases as well as to more stringently test for clinical efficacy and potential adverse effects

And for some people particularly those with long-standing diabetes these medications can be helpful when used under medical supervision

Rather, the present data would support a lower threshold of 20ng/mL (50nmol/L), which is typically optimal for the majority to maintain bone health

Endotext.org

Any scientific references on this page are provided only for research context and are not claims of therapeutic benefit

J Pediatr 182:223-231.e3, 2017